Chembio Diagnostics, Inc. engages in the developing, manufacturing, marketing, and licensing of rapid medical tests. The company is headquartered in Medford, New York and currently employs 188 full-time employees. The company went IPO on 2000-10-18. Its product portfolio is based upon its DPP technology, a diagnostic platform that provides results in 15 to 20 minutes using fingertip blood, nasal swabs, and other sample types. The DPP technology platform addresses the rapid diagnostic test market, which includes infectious diseases such as sexually transmitted infections (STIs) and human immunodeficiency virus (HIV), gastroenterology, and women's health. Its products include COVID-19 Antibody Test System, COVID-19 Antigen Test System, COVID-19 and Influenza Respiratory Antigen Panel Test System and HIV-Syphilis Diagnostic Test Systems, among others. The company is also targeting lateral flow test solutions for infectious diseases.

Industry: Pharmaceutical Preparations Peers: Arch Therapeutics, Inc. Nexgel Inc Rapid Therapeutic Science Laboratories, Inc. Innovative Eyewear Inc Rockwell Medical Inc Sharps Technology Inc Vycor Medical Inc